Angehefteter Tweet
**Why Cancer Cures Were Delayed by Red Tape**
Cancer reprogramming, using CRISPR and PSC-derived organoids, could have transformed treatment long ago, but regulatory hurdles stalled progress. Here’s how reduced red tape could have led to effective cancer cures, tied to our discussion on reprogramming and KAIST’s colon cancer work.
- **Tech Existed for Decades**:
- CRISPR (2012) and earlier gene-editing tools (1990s) enabled targeting cancer mutations.
- PSC organoids (2000s) allowed human-relevant testing, like KAIST’s 2024 colon cancer reversion (MYB, HDAC2, FOXA2).
- Lab-grown blood/tissues (2010s) offered ethical testing platforms.
- **Red Tape Slowed Progress**:
- FDA/EMA’s 5–10-year trial requirements delayed therapies like KAIST’s reversion.
- Therapy tweaks need re-approvals, stalling innovation.
- High costs ($1–2B/drug) deter investment in novel approaches.
- **Impact of Less Red Tape**:
- **Faster Trials**: Organoid data could cut timelines by 50%, enabling human trials by mid-2010s.
- **Wider Reach**: Rapid testing on organoids could extend reprogramming to breast, lung cancers.
- **Personalized Therapies**: Patient-specific organoids could tailor treatments, speeding delivery.
- **Cheaper Treatments**: Lower regulatory costs via organoid testing would improve access.
- **Missed Opportunities**:
- Reprogramming could have achieved 90–98% early-stage survival rates by now.
- Could have replaced chemotherapy with targeted reversion, reducing side effects.
- Lab-grown blood could have ensured safe integration, bypassing animal tests.
- **Why Delays Persist**:
- Early gene therapy failures (e.g., 1999) led to strict safety rules, overcomplicating approvals.
- Bureaucracy prioritizes exhaustive data over innovation.
- Focus on profitable diseases sidelines rare cancers.
- **Path Forward**:
- Push for organoid data in regulatory approvals to skip lengthy trials.
- Standardize global regulations for faster therapy rollout.
- Fund PSC research for scalable, affordable cures.
**Conclusion**: CRISPR, organoids, and lab-grown blood could have made cancer manageable years ago, with reprogramming potentially curing many types. Red tape, though safety-driven, delayed progress. Streamlining approvals with organoid data can unlock cures faster and equitably.
English
